ABIONYX PHARMA overview

Regulatory News: ABIONYX Pharma (Paris:ABNX): Market: Euronext Paris, Compartment C ISIN code: FR0012616852 Date Number of shares outstanding Total voting rights Total gross (1) Total net (2) March 31, 2025 34,931,012 44,492,548 44,198,744 (1) The total number of gross (or “theoretical”) voting rights is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting...

Regulatory News: ABIONYX Pharma (FR0012616852 - ABNX - PEA PME eligible), next-generation biopharma dedicated to the development of innovative biomedicines based on recombinant apolipoprotein apoA-I for the treatment of the most severe inflammatory diseases, today announced that CIC Market Solutions, part of Crédit Mutuel Alliance Fédérale, one of Europe's leading banking groups, has initiated coverage of its stock. In its initial coverage study published on March 20, 2025, CIC Market...

Regulatory News: ABIONYX Pharma (FR0012616852 - ABNX - PEA PME eligible), a next generation biopharma company dedicated to the development of innovative biomedicines based on a recombinant apolipoprotein apoA-1 for the treatment of the most severe inflammatory diseases, announces that it has filed with the “ Autorité des Marchés Financiers ” (AMF) its Universal Registration Document for the year ended December 31, 2024, dated March 14, 2025. ABIONYX Pharma's Universal Registration Document...

Regulatory News: ABIONYX Pharma, (FR0012616852 - ABNX - eligible for PEA PME) , a next generation biopharma company dedicated to the development of innovative biomedicines based on a recombinant apolipoprotein apoA-1 for the treatment of the most severe inflammatory diseases, today reports its 2024 full-year results as approved by the Board of Directors at its meeting of March 4, 2025. The audit procedures on the consolidated accounts have been carried out. The certification report has not been...

Regulatory News: ABIONYX Pharma (Paris:ABNX): Market: Euronext Paris, Compartment C ISIN code: FR0012616852 Date Number of shares outstanding Total voting rights Total gross (1) Total net (2) February 28, 2025 34,931,012 44,492,493 44,197,190 (1) The total number of gross (or “theoretical”) voting rights is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which...

Regulatory News: ABIONYX Pharma, (FR0012616852 - ABNX - eligible for PEA PME) , a next generation biopharma company dedicated to the development of innovative biomedicines based on a recombinant apolipoprotein apoA-1 for the treatment of the most severe inflammatory diseases, today provides an update on its progress and confirms its commitment to the rare disease known as LCAT Deficiency or ‘Norum's disease’. Commitment to the LCAT patient community for the creation of a patient association...

ABIONYX Pharma, (FR0012616852 - ABNX - eligible for PEA PME) , a next generation biopharma company dedicated to the development of innovative biomedicines based on a recombinant apolipoprotein apoA-1 for the treatment of the most severe inflammatory diseases, today provides an update on its progress and confirms its commitment to the rare disease known as LCAT Deficiency or ‘Norum's disease’. About ABIONYX Pharma ABIONYX Pharma is a next-generation biopharma company dedicated to the...

Regulatory News: ABIONYX Pharma, (FR0012616852 - ABNX - eligible for PEA PME) , a next generation biopharma company dedicated to the development of innovative biomedicines based on a recombinant apolipoprotein apoA-1 for the treatment of the most severe inflammatory diseases, today provides an update on its business and its cash position as of December 31, 2024. Selected financial information (IFRS) m€ 2024 2023 Revenue from biotech activity 0.00 0.00 Revenue from IRIS Pharma 4.55 4.64 Total...